期刊文献+

Modeling the Long-term Antibody Response and Duration of Immune Protection Induced by an Inactivated,Preservative-free Hepatitis A Vaccine(Healive)in Children

在线阅读 下载PDF
导出
摘要 Objective Long-term seroprotection via the hepatitis A vaccine is essential for the prevention of disease from the hepatitis A virus(HAV).Due to documented difficulties during decade-long follow-ups after receiving vaccines,statistical-modeling approaches have been applied to predict the duration of immune protection.Methods Based on five-year follow-up data from a randomized positive-controlled trial among Chinese children(1–8 years old)following a 0,6 months vaccination schedule,a power-law model accounting for the kinetics of B-cell turnover,as well as a modified power-law model considering a memory-B-cell subpopulation,were fitted to predict the long-term immune responses induced by HAV vaccination(Healive or Havrix).Anti-HAV levels of each individual and seroconversion rates up to 30 years after vaccination were predicted.Results A total of 375 participants who completed the two-dose vaccination were included in the analysis.Both models predicted that,over a life-long period,participants vaccinated with Healive would have close but slightly higher antibody titers than those of participants vaccinated with Havrix.Additionally,consistent with previous studies,more than 90%of participants were predicted to maintain seroconversion for at least 30 years.Moreover,the modified power-law model predicted that the antibody titers would reach a plateau level after nearly 15 years post-vaccination.Conclusions Based on the results of our modeling,Healive may adequately induce long-term immune responses following a 0,6 months vaccination schedule in children via induction of memory B cells to provide stable and durable immune protection.
出处 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2020年第7期484-492,共9页 生物医学与环境科学(英文版)
基金 sub-project of National Major Scientific and Technological Special Project of China for‘Significant New Drugs Development’[2015ZX09501008-004]。
  • 相关文献

参考文献2

二级参考文献14

  • 1庄辉.病毒性肝炎的流行病学[J].中国计划免疫,2004,10(3):180-181. 被引量:64
  • 2苏美芳,刘灿磊,王自若.一起甲型肝炎爆发的调查报告[J].中国计划免疫,2005,11(2):95-95. 被引量:2
  • 3徐建荣,叶众,杨存军,郑广勇,高丽.应用甲型肝炎灭活疫苗控制甲型肝炎爆发的研究[J].中国计划免疫,2007,13(1):66-68. 被引量:12
  • 4Theilmann L, Kallinowski B, Gmelin K, et al. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine. Vaccine, 1992,10 Suppl:S132-134.
  • 5Kenneth Z, Jessica D, Paul K, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J, 2001,20:740-746.
  • 6WHO. Hepatitis A vaccines. WER, 2000, 75(5) :37-44.
  • 7卫生部公布2006年全国法定传染病疫情附件.卫生部公布2006年全国法定传染病疫情,2007[OL].http://www.chinacdc.net.cn/n272442/n272530/n272757/appendix.
  • 8International Clinical Studies Support Center. Division of Microbiology and Infectious Diseases(DMID) Pediatric Toxicity Table (greater than 3 months of age) ,2003[OL], http://www. icssc. org/index.htm.
  • 9CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization praetices(ACIP). MMWR,2006,55(RR-7) :1-23.
  • 10北京科兴生物制品有限公司上报不良反应监测中心(ADR)资料.全国药品不良反应检测网络药品不良反应/事件报告,2002-2006.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部